Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the call in details and an updated agenda for the shareholder conference call on Thursday May 6, 2021 at 9:00 AM.
Due to a significant rise in the number of participants during recent calls, we are adding new conference call options. This will allow for easier call-in access for all callers & correct the question & answer issues that occurred during our last call.
You are now able to pre-register for the conference call by using the Direct RSVP link below. You will receive, via email, a personal Conference Pin Code allowing you to check yourself into the Conference Call. The Direct RSVP link will be available up until one hour before the call.
Participants may send pre-conference call questions to email@example.com. Questions will be reviewed by President & CEO Joseph Moscato and will be directly answered on the call, or during the corporate presentation.
Additionally, callers can also join the Conference Call the same way you have in the past by dialing in & listening to the presentation and Q&A portion. If during the call you would like to ask a question and you have not pre-registered, you will have to provide your personal information to the operator.
We have added these options for you, our shareholders, to make it easier for you to join the call and to have your questions answered. We do suggest all participants pre-register for the call by using the DirectRSVP link option for best results.
Call in Information:
Mr. Moscato said, “I look forward to Thursday morning’s call to give our shareholders an update of all corporate activities. Including an Ii-Key-SARS-CoV-2 Complete Vaccine™ progress report, the build out and launch of our Arizona operations and the recent developments with our Olaregen Excellegan products.”
About Generex Biotechnology Corp.
About NuGenerex Immuno-Oncology
Cautionary Note Regarding Forward-Looking Statements
The New World of Remote Work
JSON Within A Relational Database